Merit Medical Systems has acquired View Point Medical, Inc. in a transaction valued at approximately $140 million, expanding its therapeutic oncology capabilities.
Under the terms of the deal, Merit paid $90 million in cash at closing, with two additional payments of $25 million each due on the first and second anniversaries of the closing date. View Point becomes a wholly owned subsidiary of Merit following the merger.
View Point, based in Carlsbad, California, develops the OneMark Detection Imaging System and OneMark Tissue Markers, technologies designed to improve tissue localization during biopsy and surgical procedures. The system is cleared by the U.S. Food and Drug Administration and enables physicians to detect and visualize tissue markers across imaging modalities, helping guide more precise breast cancer surgeries.
Merit said the acquisition strengthens its position in wire-free, non-radioactive breast localization and complements its existing SCOUT platform. The combined technologies are intended to allow earlier and more accurate localization of tumors at the time of biopsy, potentially reducing the need for additional procedures prior to surgery.
The company expects the acquisition to contribute between $2 million and $4 million in revenue for the remainder of 2026 and between $14 million and $16 million in 2027. Sales of the OneMark system are projected to grow at least 20% annually, with strong gross margins and long-term accretion to non-GAAP earnings.
Merit noted the transaction may be dilutive to GAAP earnings in the near term but is expected to become accretive over time as integration progresses and product adoption increases.
KEY QUOTES:
“This acquisition expands Merit’s portfolio of therapeutic oncology products dedicated to the accurate diagnosis and localization of breast and soft tissue tumors. Merit has built a market leadership position in wire-free, non-radioactive breast localization procedures. This leadership is built upon our SCOUT platform, which utilizes the precision and accuracy of radar. View Point’s unique ultrasound-enhanced technology offers a highly innovative solution to localize more lesions at the time of biopsy – representing an estimated 1.3 million procedures annually in the United States alone. We look forward to discussing this acquisition in further detail on our first quarter investor conference call.”
Martha G. Aronson, President And Chief Executive Officer, Merit Medical Systems
“The acquisition of View Point reinforces Merit’s mission to help reduce the burden that breast cancer places on patients and their loved ones. As treatment protocols evolve, the suspicious area is often most visible at the time of biopsy. Localizing these areas early in a patient’s cancer journey can help physicians plan treatment and may help reduce the need for additional localization procedures.”
Adam Smith, Chief Commercial Officer, Merit Medical Systems
